Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion type Assertion NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_head.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion description "[In addition to conventional therapy, current treatment of thalassemia and sickle cell anemia includes inducers of hemoglobin F synthesis (hydroxyurea, erythropoietin, azacytidine and butyrate).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_provenance.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion evidence source_evidence_literature NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_provenance.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion SIO_000772 11454524 NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_provenance.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion wasDerivedFrom befree-20140225 NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_provenance.
- NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_assertion wasGeneratedBy ECO_0000203 NP531050.RAc4vevyN8-tOCVq-ZPT_ees7rpfsgwjdiKNhlMennR2w130_provenance.